Treace Medical Concepts (NASDAQ: TMCI) has announced that it will be releasing its financial results for the third quarter of 2024 on Tuesday 5th November 2024. The report will be made available after market close, allowing investors and analysts to evaluate the company's performance during this period.
Wall Street financial analysts are foreseeing that the company is likely to announce an estimated per share $0.27 loss for the quarter. Furthermore, it is anticipated that the company will disclose a total revenue of $43.48 million during the quarter.
In the same quarter of the previous year, the company's financial statement revealed a per-share loss of $0.28. Additionally, the company's overall revenue for that particular period was an impressive $40.76 million.
Financial experts on Wall Street have shared their predictions regarding the company's annual performance, estimating a total revenue of $205.97 million. Additionally, they are expecting the company to report loss of $0.94 per share for the full year 2024.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $-0.34 | -70.0% | 44.46 M | +6.0% |
| Q1 2024 | $-0.30 | -30.4% | 51.11 M | +21.1% |
| Q4 2023 | $-0.10 | -25.0% | 62.21 M | +25.0% |
| Q3 2023 | $-0.28 | -27.3% | 40.76 M | +23.3% |
| Q2 2023 | $-0.20 | +13.0% | 41.95 M | +40.0% |
| *Growth on year-over-year basis | ||||
TMCI has scheduled a conference call on 5th November 2024 at 04:30 PM eastern time to discuss the third quarter financial results and other related information.
Treace Medical Concepts (TMCI) closed Friday's regular trading session at $4.78, indicating a 2.58 percent increase, with a volume of 526.60 thousand shares.
